Amar Surabhi, Roy Vivek, Perez Edith A
Jacksonville, Florida 32224, USA.
Expert Opin Pharmacother. 2007 Aug;8(12):1965-75. doi: 10.1517/14656566.8.12.1965.
State of the art hormonal therapy for women with breast cancer has evolved over the last few years. Tamoxifen used to be the gold standard for adjuvant treatment of postmenopausal women with hormone-sensitive early breast cancer and also for patients with metastatic disease in whom hormonal manipulation was considered, but the introduction of third generation aromatase inhibitors has changed this concept. This article discusses the clinical implications of recent trials with one of the aromatase inhibitors letrozole, including pharmacokinetic and pharmacodynamic data as well as recent data on relative benefits and side effects compared with other available hormonal agents. Relevant ongoing clinical-translational trials evaluating this agent are also discussed.
过去几年，针对乳腺癌女性患者的前沿激素疗法不断发展。他莫昔芬曾是绝经后激素敏感性早期乳腺癌辅助治疗以及考虑进行激素干预的转移性疾病患者的金标准，但第三代芳香化酶抑制剂的出现改变了这一观念。本文讨论了芳香化酶抑制剂来曲唑近期试验的临床意义，包括药代动力学和药效学数据，以及与其他可用激素药物相比的相对获益和副作用的最新数据。还讨论了评估该药物的相关正在进行的临床转化试验。
